| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toll-Like Receptor 9 | 25 | 2013 | 197 | 4.200 |
Why?
|
| Oligonucleotides | 31 | 2024 | 208 | 3.860 |
Why?
|
| Toll-Like Receptor 7 | 12 | 2013 | 97 | 3.560 |
Why?
|
| Oligodeoxyribonucleotides | 14 | 2010 | 243 | 3.080 |
Why?
|
| Toll-Like Receptor 8 | 9 | 2013 | 44 | 2.700 |
Why?
|
| CpG Islands | 18 | 2009 | 212 | 2.540 |
Why?
|
| Adjuvants, Immunologic | 15 | 2010 | 228 | 2.500 |
Why?
|
| Oligoribonucleotides | 7 | 2013 | 14 | 1.970 |
Why?
|
| Immunologic Factors | 12 | 2009 | 99 | 1.920 |
Why?
|
| RNA | 4 | 2024 | 404 | 1.760 |
Why?
|
| Th1 Cells | 9 | 2013 | 170 | 1.760 |
Why?
|
| Spleen | 19 | 2010 | 485 | 1.550 |
Why?
|
| Cytokines | 24 | 2013 | 906 | 1.330 |
Why?
|
| Mice | 48 | 2013 | 10253 | 1.030 |
Why?
|
| Membrane Glycoproteins | 6 | 2013 | 669 | 1.010 |
Why?
|
| Cells, Cultured | 21 | 2013 | 2103 | 0.940 |
Why?
|
| Nucleic Acids | 1 | 2024 | 50 | 0.860 |
Why?
|
| DNA | 8 | 2009 | 793 | 0.850 |
Why?
|
| Mice, Inbred C57BL | 23 | 2013 | 3186 | 0.830 |
Why?
|
| Animals | 56 | 2013 | 19607 | 0.820 |
Why?
|
| Mice, Inbred BALB C | 20 | 2012 | 880 | 0.810 |
Why?
|
| Deoxyguanosine | 4 | 2007 | 20 | 0.790 |
Why?
|
| Dendritic Cells | 9 | 2012 | 509 | 0.720 |
Why?
|
| Receptors, Cell Surface | 6 | 2005 | 439 | 0.720 |
Why?
|
| Drug Design | 5 | 2013 | 143 | 0.710 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2013 | 810 | 0.650 |
Why?
|
| Genetic Therapy | 2 | 2020 | 734 | 0.590 |
Why?
|
| Base Sequence | 11 | 2013 | 1312 | 0.580 |
Why?
|
| Interleukin-12 | 11 | 2011 | 124 | 0.550 |
Why?
|
| Nucleic Acid Conformation | 3 | 2009 | 231 | 0.550 |
Why?
|
| B-Lymphocytes | 7 | 2014 | 550 | 0.530 |
Why?
|
| Gene Silencing | 2 | 2011 | 377 | 0.510 |
Why?
|
| Cell Line | 12 | 2011 | 2014 | 0.500 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2013 | 156 | 0.480 |
Why?
|
| DNA-Binding Proteins | 6 | 2013 | 1128 | 0.480 |
Why?
|
| Toll-Like Receptor 3 | 2 | 2013 | 67 | 0.480 |
Why?
|
| NF-kappa B | 9 | 2013 | 461 | 0.470 |
Why?
|
| Deoxyribonucleotides | 1 | 2013 | 1 | 0.440 |
Why?
|
| Immunity | 3 | 2010 | 96 | 0.430 |
Why?
|
| Th17 Cells | 1 | 2013 | 52 | 0.420 |
Why?
|
| RNA, Antisense | 2 | 2020 | 48 | 0.420 |
Why?
|
| Down-Regulation | 2 | 2013 | 306 | 0.410 |
Why?
|
| Psoriasis | 1 | 2013 | 51 | 0.410 |
Why?
|
| Female | 34 | 2013 | 30799 | 0.410 |
Why?
|
| Structure-Activity Relationship | 7 | 2009 | 376 | 0.380 |
Why?
|
| Th2 Cells | 3 | 2007 | 98 | 0.350 |
Why?
|
| Interferon-alpha | 3 | 2010 | 99 | 0.340 |
Why?
|
| Arabinonucleotides | 1 | 2009 | 4 | 0.320 |
Why?
|
| RNA, Messenger | 5 | 2011 | 1470 | 0.320 |
Why?
|
| Humans | 37 | 2020 | 59302 | 0.320 |
Why?
|
| Inflammasomes | 1 | 2013 | 331 | 0.320 |
Why?
|
| Lymphocytes | 4 | 2005 | 194 | 0.310 |
Why?
|
| Interferon-gamma | 6 | 2010 | 537 | 0.300 |
Why?
|
| Toll-Like Receptors | 4 | 2014 | 434 | 0.300 |
Why?
|
| Peanut Hypersensitivity | 1 | 2007 | 4 | 0.290 |
Why?
|
| Interleukin-6 | 6 | 2009 | 309 | 0.280 |
Why?
|
| Splenomegaly | 5 | 2006 | 22 | 0.280 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2013 | 209 | 0.280 |
Why?
|
| Lymphocyte Activation | 4 | 2010 | 740 | 0.270 |
Why?
|
| Peptides | 1 | 2010 | 548 | 0.260 |
Why?
|
| Deoxyribonucleosides | 2 | 2003 | 3 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2006 | 399 | 0.260 |
Why?
|
| Camptothecin | 2 | 2002 | 23 | 0.250 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2005 | 16 | 0.250 |
Why?
|
| Neoplasms, Experimental | 2 | 2002 | 73 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2009 | 454 | 0.250 |
Why?
|
| Immunity, Mucosal | 1 | 2005 | 46 | 0.240 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2005 | 133 | 0.240 |
Why?
|
| Immunotherapy | 3 | 2007 | 229 | 0.240 |
Why?
|
| Ethidium | 1 | 2004 | 2 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 6 | 2006 | 454 | 0.230 |
Why?
|
| Immunity, Innate | 4 | 2024 | 766 | 0.230 |
Why?
|
| Bisbenzimidazole | 1 | 2004 | 3 | 0.230 |
Why?
|
| Gene Targeting | 1 | 2004 | 82 | 0.230 |
Why?
|
| Staining and Labeling | 1 | 2004 | 124 | 0.220 |
Why?
|
| Eustachian Tube | 3 | 2007 | 8 | 0.210 |
Why?
|
| Otitis Media with Effusion | 3 | 2007 | 8 | 0.210 |
Why?
|
| 5' Flanking Region | 4 | 2003 | 9 | 0.210 |
Why?
|
| Mice, Nude | 7 | 2006 | 259 | 0.210 |
Why?
|
| Lung Neoplasms | 5 | 2012 | 546 | 0.210 |
Why?
|
| Immunity, Cellular | 2 | 2009 | 176 | 0.210 |
Why?
|
| Chemokines | 4 | 2009 | 94 | 0.210 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2002 | 87 | 0.210 |
Why?
|
| Dinucleoside Phosphates | 1 | 2003 | 38 | 0.210 |
Why?
|
| Neoplasms | 4 | 2006 | 1234 | 0.210 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2013 | 125 | 0.200 |
Why?
|
| Interleukin-5 | 4 | 2007 | 39 | 0.200 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 260 | 0.190 |
Why?
|
| Colonic Neoplasms | 4 | 2010 | 213 | 0.190 |
Why?
|
| Disease Models, Animal | 7 | 2013 | 2061 | 0.190 |
Why?
|
| Immune System | 1 | 2002 | 129 | 0.190 |
Why?
|
| Cell Division | 4 | 2003 | 442 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2009 | 238 | 0.180 |
Why?
|
| Macaca fascicularis | 2 | 2013 | 47 | 0.180 |
Why?
|
| Immunologic Memory | 3 | 2010 | 276 | 0.180 |
Why?
|
| Telomerase | 2 | 2010 | 30 | 0.170 |
Why?
|
| Ribonucleases | 2 | 2009 | 31 | 0.170 |
Why?
|
| Lung | 1 | 2004 | 823 | 0.170 |
Why?
|
| Asthma | 1 | 2004 | 417 | 0.170 |
Why?
|
| DNA Primers | 2 | 2011 | 291 | 0.170 |
Why?
|
| 3' Flanking Region | 3 | 2003 | 7 | 0.160 |
Why?
|
| Immunoglobulin G | 3 | 2007 | 451 | 0.160 |
Why?
|
| Antineoplastic Agents | 4 | 2012 | 643 | 0.160 |
Why?
|
| Amino Acid Motifs | 3 | 2014 | 152 | 0.160 |
Why?
|
| Vaccines, DNA | 2 | 2010 | 99 | 0.160 |
Why?
|
| Organ Size | 3 | 2003 | 163 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 851 | 0.160 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 3 | 2006 | 8 | 0.150 |
Why?
|
| Cell Line, Tumor | 6 | 2014 | 1370 | 0.150 |
Why?
|
| Transfection | 3 | 2011 | 673 | 0.140 |
Why?
|
| Macrophages | 3 | 2013 | 1006 | 0.140 |
Why?
|
| Neoplasm Transplantation | 4 | 2009 | 158 | 0.140 |
Why?
|
| HEK293 Cells | 3 | 2014 | 577 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2013 | 2890 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 1977 | 0.130 |
Why?
|
| Immunoglobulin E | 2 | 2007 | 85 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 869 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2007 | 345 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2010 | 180 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2010 | 83 | 0.120 |
Why?
|
| Ligands | 2 | 2009 | 422 | 0.120 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Adaptor Protein Complex 2 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2013 | 944 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2013 | 1987 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2020 | 617 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 119 | 0.110 |
Why?
|
| Allergens | 2 | 2004 | 43 | 0.110 |
Why?
|
| Mice, Inbred NZB | 1 | 2013 | 19 | 0.110 |
Why?
|
| Ovalbumin | 4 | 2007 | 112 | 0.110 |
Why?
|
| Male | 12 | 2013 | 27481 | 0.110 |
Why?
|
| Sequence Deletion | 2 | 2004 | 114 | 0.110 |
Why?
|
| Injections, Intradermal | 1 | 2013 | 5 | 0.110 |
Why?
|
| Mice, Inbred C3H | 2 | 2003 | 174 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2012 | 134 | 0.110 |
Why?
|
| Interleukin-23 | 1 | 2013 | 18 | 0.110 |
Why?
|
| Survival Rate | 3 | 2004 | 787 | 0.100 |
Why?
|
| Interleukins | 2 | 2002 | 77 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2013 | 174 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2012 | 553 | 0.100 |
Why?
|
| Monocytes | 1 | 2014 | 351 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2005 | 439 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 2 | 2009 | 51 | 0.100 |
Why?
|
| Species Specificity | 2 | 2003 | 336 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 169 | 0.100 |
Why?
|
| Sequence Alignment | 1 | 2013 | 290 | 0.100 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2012 | 7 | 0.100 |
Why?
|
| Myocardium | 1 | 2013 | 262 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 201 | 0.100 |
Why?
|
| Gastrointestinal Agents | 1 | 2012 | 29 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 354 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2013 | 595 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 73 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 265 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2010 | 353 | 0.090 |
Why?
|
| Kidney | 1 | 2013 | 391 | 0.090 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 256 | 0.090 |
Why?
|
| Breast Neoplasms | 3 | 2009 | 1126 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2013 | 710 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2006 | 132 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2010 | 48 | 0.080 |
Why?
|
| Vaccination | 1 | 2012 | 337 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 183 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 322 | 0.080 |
Why?
|
| Epitopes | 1 | 2010 | 298 | 0.080 |
Why?
|
| Transition Temperature | 1 | 2008 | 5 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 81 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 673 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 62 | 0.080 |
Why?
|
| Amyloid beta-Peptides | 1 | 2010 | 189 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 196 | 0.080 |
Why?
|
| Plasmids | 1 | 2009 | 282 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 759 | 0.070 |
Why?
|
| Rats | 5 | 2012 | 1907 | 0.070 |
Why?
|
| Guanine | 2 | 2006 | 22 | 0.070 |
Why?
|
| Interleukin-13 | 1 | 2007 | 35 | 0.070 |
Why?
|
| RNA Stability | 1 | 2007 | 93 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2006 | 16 | 0.070 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2006 | 2 | 0.070 |
Why?
|
| Deoxycytosine Nucleotides | 1 | 2006 | 4 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2006 | 222 | 0.070 |
Why?
|
| Interleukin-10 | 2 | 2009 | 146 | 0.070 |
Why?
|
| Intestines | 1 | 2007 | 157 | 0.070 |
Why?
|
| Aluminum Hydroxide | 1 | 2005 | 3 | 0.060 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 32 | 0.060 |
Why?
|
| Haplorhini | 1 | 2005 | 14 | 0.060 |
Why?
|
| Electroporation | 3 | 2010 | 32 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2005 | 39 | 0.060 |
Why?
|
| Digestive System | 1 | 2005 | 25 | 0.060 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2005 | 106 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 131 | 0.060 |
Why?
|
| Nucleotides | 1 | 2005 | 42 | 0.060 |
Why?
|
| AIDS Vaccines | 1 | 2005 | 67 | 0.060 |
Why?
|
| Neutrophils | 1 | 2007 | 354 | 0.060 |
Why?
|
| Macaca mulatta | 3 | 2011 | 247 | 0.060 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2004 | 7 | 0.060 |
Why?
|
| Adenoviridae | 3 | 2010 | 119 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2005 | 82 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 135 | 0.060 |
Why?
|
| Airway Resistance | 1 | 2004 | 8 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 140 | 0.060 |
Why?
|
| Arthritis | 1 | 2004 | 49 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2004 | 90 | 0.060 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2004 | 29 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2005 | 363 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 97 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2004 | 145 | 0.060 |
Why?
|
| Body Weight | 2 | 2002 | 378 | 0.060 |
Why?
|
| Cytosine | 1 | 2003 | 30 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2005 | 343 | 0.060 |
Why?
|
| Eosinophils | 1 | 2004 | 51 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 142 | 0.060 |
Why?
|
| Conalbumin | 1 | 2003 | 1 | 0.050 |
Why?
|
| Rats, Inbred BN | 3 | 2007 | 25 | 0.050 |
Why?
|
| Intercalating Agents | 1 | 2003 | 2 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 38 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 671 | 0.050 |
Why?
|
| Ethylene Glycol | 1 | 2002 | 7 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 183 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 125 | 0.050 |
Why?
|
| Enzyme Stability | 1 | 2002 | 46 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2002 | 30 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2002 | 326 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2002 | 38 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 201 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2002 | 112 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 300 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 427 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2003 | 375 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 733 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2009 | 219 | 0.050 |
Why?
|
| Pneumonia | 1 | 2004 | 263 | 0.050 |
Why?
|
| RNA Interference | 1 | 2004 | 589 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2002 | 321 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2003 | 861 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 1550 | 0.040 |
Why?
|
| Binding Sites | 1 | 2003 | 875 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 196 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 315 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 742 | 0.040 |
Why?
|
| Trastuzumab | 2 | 2009 | 11 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1537 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2010 | 214 | 0.040 |
Why?
|
| Time Factors | 1 | 2005 | 3567 | 0.040 |
Why?
|
| Inflammation | 1 | 2004 | 1101 | 0.040 |
Why?
|
| Injections, Subcutaneous | 2 | 2007 | 70 | 0.030 |
Why?
|
| Apoptosis | 3 | 2006 | 1038 | 0.030 |
Why?
|
| Random Allocation | 2 | 2007 | 198 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2007 | 576 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 11 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2002 | 5141 | 0.030 |
Why?
|
| Cell Survival | 2 | 2007 | 553 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2005 | 149 | 0.030 |
Why?
|
| Myoblasts, Skeletal | 1 | 2013 | 12 | 0.030 |
Why?
|
| Mice, Inbred mdx | 1 | 2013 | 18 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2006 | 282 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 1093 | 0.030 |
Why?
|
| Dystrophin | 1 | 2013 | 35 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 394 | 0.030 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2013 | 42 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2012 | 27 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2012 | 27 | 0.030 |
Why?
|
| Radiation-Protective Agents | 1 | 2012 | 3 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2012 | 18 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 47 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 173 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 96 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 141 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 576 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 15 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 47 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2010 | 42 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 1155 | 0.020 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2009 | 16 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 90 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 42 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 28 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 78 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 694 | 0.020 |
Why?
|
| Dimerization | 1 | 2009 | 146 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 172 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 176 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 170 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1039 | 0.020 |
Why?
|
| Cetuximab | 1 | 2007 | 8 | 0.020 |
Why?
|
| Tympanic Membrane | 1 | 2007 | 10 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2007 | 56 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2007 | 211 | 0.020 |
Why?
|
| Taxoids | 1 | 2006 | 26 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2006 | 11 | 0.020 |
Why?
|
| Glutamates | 1 | 2006 | 14 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2006 | 28 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2006 | 39 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2007 | 177 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 33 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 201 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 177 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 293 | 0.020 |
Why?
|
| Cell Movement | 1 | 2007 | 422 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1221 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 963 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 525 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2004 | 8 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 484 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 2005 | 141 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2005 | 139 | 0.010 |
Why?
|
| Interferon-beta | 1 | 2004 | 76 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 434 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 338 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 164 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 697 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 580 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 3095 | 0.010 |
Why?
|
| Middle Aged | 1 | 2009 | 16232 | 0.010 |
Why?
|